Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Molecular Templates price target lowered to $9 from $11 at Stifel » 14:36
05/13/22
05/13
14:36
05/13/22
14:36
MTEM

Molecular Templates

$1.20 /

+0.03 (+2.56%)

Stifel analyst Stephen…

Stifel analyst Stephen Willey lowered the firm's price target on Molecular Templates to $9 from $11 and keeps a Buy rating on the shares following the company's Q1 earnings report and corporate update. His updated target mostly reflects revised financing assumptions, noted Willey, who believes FY22 will be "a critical year for securing more visibility into the prospects of the clinical-stage pipeline and platform."

ShowHide Related Items >><<
MTEM Molecular Templates
$1.20 /

+0.03 (+2.56%)

MTEM Molecular Templates
$1.20 /

+0.03 (+2.56%)

03/30/22 Barclays
Molecular Templates price target lowered to $4.50 from $8 at Barclays
MTEM Molecular Templates
$1.20 /

+0.03 (+2.56%)

Earnings
Molecular Templates reports Q1 EPS (38c), consensus (47c) » 05:46
05/13/22
05/13
05:46
05/13/22
05:46
MTEM

Molecular Templates

$1.18 /

-0.025 (-2.08%)

Reports Q1 revenue…

Reports Q1 revenue $8.49M, consensus $5.14M. "We continue to make meaningful progress in advancing our pipeline of ETBs," said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. "We recently commenced dosing in Cohort 3 of our Phase 1 study of MT-6402 in PD-L1+ patients. We intend to report additional data from this study in the second half of the year. Dose finding in the MT-5111 and MT-0169 programs is ongoing with clinical data expected this year. We look forward to continued momentum across our pipeline in 2022, including filing an IND for MT-8421, our ETB targeting CTLA-4, and advancing our earlier stage pipeline of ETBs targeting TIGIT, TROP-2, and BCMA."

ShowHide Related Items >><<
MTEM Molecular Templates
$1.18 /

-0.025 (-2.08%)

MTEM Molecular Templates
$1.18 /

-0.025 (-2.08%)

03/30/22 Barclays
Molecular Templates price target lowered to $4.50 from $8 at Barclays
MTEM Molecular Templates
$1.18 /

-0.025 (-2.08%)

Hot Stocks
Molecular Templates sees cash, investments funding operations to end of 2023  16:37
05/12/22
05/12
16:37
05/12/22
16:37
MTEM

Molecular Templates

$1.18 /

-0.025 (-2.08%)

 
ShowHide Related Items >><<
MTEM Molecular Templates
$1.18 /

-0.025 (-2.08%)

MTEM Molecular Templates
$1.18 /

-0.025 (-2.08%)

03/30/22 Barclays
Molecular Templates price target lowered to $4.50 from $8 at Barclays
MTEM Molecular Templates
$1.18 /

-0.025 (-2.08%)

Over a month ago
Hot Stocks
Molecular Templates reviews six poster presentations at AACR 2022 meeting » 07:41
04/12/22
04/12
07:41
04/12/22
07:41
MTEM

Molecular Templates

$2.89 /

-0.23 (-7.37%)

Molecular Templates…

Molecular Templates reviews highlights from the six poster presentations on its pipeline programs that were presented at the American Association of Cancer Research, AACR, Annual Meeting 2022. Poster Title: A Phase 1 Study of MT-6402, a novel Engineered Toxin Body targeting PD-L1, in patients with PD-L1 expressing advanced solid tumors: Twelve patients with PD-L1+ relapsed/refractory disease have been treated to date across two dose cohorts: 16 mcg/kg and 24 mcg/kg. Pharmacodynamic, PD, effects including monocyte and myeloid-derived suppressor cell depletion and T cell activation have been observed in the majority of patients. One patient in the first cohort with non-small cell lung cancer that had progressed after prior checkpoint therapy showed qualitative reduction in tumor burden. One dose-limiting toxicity, DLT, was observed in a single patient. No other DLTs have been reported. Poster Title: Altering tumor immunophenotypes with PD-L1 engineered toxin bodies. Molecular Templates' Antigen Seeding Technology is a unique approach that allows for specific alteration of tumor immunophenotype to match pre-existing CD8+ T-cells in a patient. Data demonstrated that MT-6402 can be altered to present antigens derived from CMV corresponding to other HLA genotypes. Poster Title: A CTLA-4-targeted ETB for Treg depletion shows favorable preclinical efficacy and safety. CTLA-4-targeted ETBs are designed to preferentially deplete regulatory T cells, via a direct cell kill mechanism of action that is independent of effector cells. In a transgenic mouse model expressing human CTLA-4 and bearing syngeneic subcutaneous tumors, CTLA-4 ETB treatment depleted Tregs in the TME. CTLA-4 ETB candidate was well tolerated in a non-human primate toxicology study. Poster Title: Engineered Toxin Bodies targeting Trop2. Trop2 targeted ETBs show in vitro target specific picomolar potency on Trop2 positive tumor cell lines. AST enabled Trop2 targeted ETBs to retain direct cell kill potency and alter the tumor immunophenotype to allow for antigen specific T-cell recognition. Poster Title: Improving immunotoxin-based therapeutics for cancer with de-immunized Engineered Toxin Bodies. Molecular Templates has developed a de-immunized form of Shiga-like Toxin A incorporated into next-generation ETBs currently in clinical trials. Ex vivo assays using peripheral blood mononuclear cells demonstrate that unmodified SLTA displays upregulation of CCL3, CCL4, TNFalpha and IL-6, indicating a similar, but not identical, pattern of cytokine release relative to the positive control, lipopolysaccharide, while the de-immunized SLTA did not activate cytokine or chemokine release. Poster Title: C-KIT/CD117 targeted ETBs for cancer therapy and HSC transplant conditioning. Poster highlights: CD117 ETB drug conjugates with MMAF demonstrated increased cytotoxicity compared to stand-alone ETBs or inactive ETB drug conjugate controls and also highlighted the internalization augmenting capabilities of ETBs.

ShowHide Related Items >><<
MTEM Molecular Templates
$2.89 /

-0.23 (-7.37%)

MTEM Molecular Templates
$2.89 /

-0.23 (-7.37%)

03/30/22 Barclays
Molecular Templates price target lowered to $4.50 from $8 at Barclays
04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
MTEM Molecular Templates
$2.89 /

-0.23 (-7.37%)

Hot Stocks
Molecular Templates to host webinar on immuno-oncology for solid tumors » 08:07
04/08/22
04/08
08:07
04/08/22
08:07
MTEM

Molecular Templates

$3.30 /

+0.05 (+1.54%)

Molecular Templates…

Molecular Templates announced that it will host a webinar on a unique approach to immuno-oncology for solid tumors on Wednesday, April 13, 2022 at 8:00 am Eastern Time. The webinar will feature a presentation from medical expert David Spigel, MD, of the Sarah Cannon Research Institute, who will discuss Molecular Templates' program, MT-6402, and the implications of the Phase 1 data as it relates to treating patients with a variety of PD-L1-expressing solid tumors. MT-6402 is the first of the Company's 3rd generation ETBs to enter the clinic. It is designed to induce potent anti-tumor effects via PD-L1 targeting through mechanisms including Shiga-like Toxin A ribosomal inactivation and CMV antigen-seeding technology, both of which may overcome the limitations of approved checkpoint inhibitors.

ShowHide Related Items >><<
MTEM Molecular Templates
$3.30 /

+0.05 (+1.54%)

MTEM Molecular Templates
$3.30 /

+0.05 (+1.54%)

03/30/22 Barclays
Molecular Templates price target lowered to $4.50 from $8 at Barclays
04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
MTEM Molecular Templates
$3.30 /

+0.05 (+1.54%)

Recommendations
Molecular Templates price target lowered to $4.50 from $8 at Barclays » 06:30
03/30/22
03/30
06:30
03/30/22
06:30
MTEM

Molecular Templates

$3.25 /

+0.53 (+19.49%)

Barclays analyst Carter…

Barclays analyst Carter Gould lowered the firm's price target on Molecular Templates to $4.50 from $8 and keeps an Overweight rating on the shares post the Q4 results.

ShowHide Related Items >><<
MTEM Molecular Templates
$3.25 /

+0.53 (+19.49%)

MTEM Molecular Templates
$3.25 /

+0.53 (+19.49%)

04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21 Jefferies
Jefferies views Molecular Templates selloff as overdone, boosts price target
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
MTEM Molecular Templates
$3.25 /

+0.53 (+19.49%)

Earnings
Molecular Templates reports Q4 EPS (18c), consensus (40c) » 16:31
03/28/22
03/28
16:31
03/28/22
16:31
MTEM

Molecular Templates

$2.73 /

+0.07 (+2.63%)

Reports Q4 revenue $18M,…

Reports Q4 revenue $18M, consensus $15.03M. "2022 is off to a very promising start, following a number of important developments across our pipeline of ETBs in 2021," said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. "We continue to see differentiated pharmacodynamic effects and evidence of antigen seeding with MT-6402 with additional data expected throughout 2022. We continue dose finding for the MT-5111 and MT-0169 programs with clinical data expected this year. We plan to file an IND in 2H22 for our CTLA-4 program and are moving forward with our earlier stage pipeline of ETBs in preclinical development targeting TIGIT, TROP-2, and BCMA."

ShowHide Related Items >><<
MTEM Molecular Templates
$2.73 /

+0.07 (+2.63%)

MTEM Molecular Templates
$2.73 /

+0.07 (+2.63%)

04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21 Jefferies
Jefferies views Molecular Templates selloff as overdone, boosts price target
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
MTEM Molecular Templates
$2.73 /

+0.07 (+2.63%)

Conference/Events
Barclays to hold a conference » 04:55
03/17/22
03/17
04:55
03/17/22
04:55
AVTR

Avantor

$34.90 /

+0.42 (+1.22%)

, PAHC

Phibro Animal Health

$19.85 /

-0.17 (-0.85%)

, CVS

CVS Health

$107.14 /

+0.12 (+0.11%)

, ALNY

Alnylam

$158.89 /

+5.92 (+3.87%)

, LNTH

Lantheus

$54.99 /

+2.38 (+4.52%)

, BEAM

Beam Therapeutics

$59.83 /

+4.67 (+8.47%)

, HUM

Humana

$442.83 /

+2.9 (+0.66%)

, CNC

Centene

$86.83 /

+1.27 (+1.48%)

, LLY

Eli Lilly

$276.42 /

+0.87 (+0.32%)

, PINC

Premier

$35.67 /

+ (+0.00%)

, AZTA

Azenta

$84.77 /

+7.52 (+9.73%)

, EXEL

Exelixis

$20.65 /

+0.36 (+1.77%)

, THC

Tenet Healthcare

$87.65 /

+0.22 (+0.25%)

, PFE

Pfizer

$52.93 /

+0.69 (+1.32%)

, TCRX

TScan Therapeutics

$3.55 /

-0.105 (-2.87%)

, VACC

Vaccitech

$5.85 /

+0.59 (+11.22%)

, VOR

Vor Bio

$7.85 /

+0.17 (+2.21%)

, SGMO

Sangamo

$5.54 /

+0.3 (+5.73%)

, SGTX

Sigilon Therapeutics

$1.42 /

+0.09 (+6.77%)

, PIII

P3 Health Partners

$6.85 /

+0.09 (+1.33%)

, JANX

Janux Therapeutics

$17.22 /

+0.19 (+1.12%)

, KPTI

Karyopharm

$6.67 /

+0.45 (+7.23%)

, EOLS

Evolus

$10.55 /

+0.61 (+6.14%)

, EPZM

Epizyme

$1.31 /

+0.11 (+9.21%)

, BKD

Brookdale Senior Living

$6.79 /

-0.155 (-2.23%)

, MTEM

Molecular Templates

$2.50 /

+0.175 (+7.53%)

, LOGC

LogicBio Therapeutics

/

+

Global Healthcare…

Global Healthcare Conference to be held in Miami, FL on March 15-17.

ShowHide Related Items >><<
VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

VACC Vaccitech
$5.85 /

+0.59 (+11.22%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

TCRX TScan Therapeutics
$3.55 /

-0.105 (-2.87%)

SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

PINC Premier
$35.67 /

+ (+0.00%)

PIII P3 Health Partners
$6.85 /

+0.09 (+1.33%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

PAHC Phibro Animal Health
$19.85 /

-0.17 (-0.85%)

MTEM Molecular Templates
$2.50 /

+0.175 (+7.53%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

JANX Janux Therapeutics
$17.22 /

+0.19 (+1.12%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

EPZM Epizyme
$1.31 /

+0.11 (+9.21%)

EOLS Evolus
$10.55 /

+0.61 (+6.14%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

AZTA Azenta
$84.77 /

+7.52 (+9.73%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

02/07/22 Raymond James
Avantor price target lowered to $43 from $47 at Raymond James
02/07/22 Baird
Avantor price target lowered to $43 from $44 at Baird
02/07/22 Barclays
Avantor price target raised to $44 from $41 at Barclays
01/27/22 Barclays
Avantor price target lowered to $41 from $48 at Barclays
PAHC Phibro Animal Health
$19.85 /

-0.17 (-0.85%)

01/10/22 Barclays
Phibro Animal Health upgraded to Equal Weight from Underweight at Barclays
11/18/21 Morgan Stanley
Phibro Animal Health initiated with an Equal Weight at Morgan Stanley
08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
CVS CVS Health
$107.14 /

+0.12 (+0.11%)

03/09/22 UBS
Signify Health upgraded to Buy from Neutral at UBS
02/17/22 Deutsche Bank
CVS Health price target raised to $110 from $107 at Deutsche Bank
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

02/28/22 Citi
Alnylam initiated with a Buy at Citi
02/10/22 Piper Sandler
Piper Sandler 'confident' in approval of Alnylam's vutrisiran by PDUFA date
02/03/22 Guggenheim
Alnylam upgraded to Buy from Neutral at Guggenheim
01/20/22 H.C. Wainwright
Alnylam price target raised to $350 from $250 at H.C. Wainwright
LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
HUM Humana
$442.83 /

+2.9 (+0.66%)

02/03/22 Deutsche Bank
Humana price target raised to $435 from $418 at Deutsche Bank
01/11/22 Bernstein
Humana price target lowered to $431 from $470 at Bernstein
01/07/22 Truist
Humana price target lowered to $445 from $520 at Truist
01/07/22 BMO Capital
Humana price target lowered to $415 from $490 at BMO Capital
CNC Centene
$86.83 /

+1.27 (+1.48%)

02/09/22 Deutsche Bank
Centene price target raised to $88 from $84 at Deutsche Bank
02/09/22 BMO Capital
Centene price target raised to $105 from $100 at BMO Capital
02/09/22 Mizuho
Centene price target raised to $84 from $78 at Mizuho
02/04/22 Wells Fargo
Anthem, Centene have 'significant' exposure to CA Medicaid, says Wells Fargo
LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

03/10/22 Daiwa
Eli Lilly initiated with an Outperform at Daiwa
03/02/22 Goldman Sachs
Quanterix upgraded to Neutral from Sell at Goldman Sachs
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
02/11/22 Benchmark
AbCellera royalties could be 'substantial' from Lilly antibody, says Benchmark
PINC Premier
$35.67 /

+ (+0.00%)

11/18/21 Barclays
Premier price target raised to $36 from $34 at Barclays
11/03/21 Piper Sandler
Premier price target raised to $39 from $31 at Piper Sandler
05/28/21
Fly Intel: Top five analyst downgrades
05/28/21 Barclays
Barclays double downgrades Premier with multiple expansion less likely
AZTA Azenta
$84.77 /

+7.52 (+9.73%)

02/09/22 Needham
Azenta price target lowered to $115 from $155 at Needham
11/17/21 Stifel
Brooks Automation price target raised to $149 from $134 at Stifel
11/17/21 Stephens
Brooks Automation price target raised to $137 from $130 at Stephens
EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

03/14/22 Piper Sandler
Exelixis price target lowered to $30 from $34 at Piper Sandler
02/25/22 Jefferies
Court denied MSN motion to add patents to fight with Exelixis, says Jefferies
02/18/22 H.C. Wainwright
Exelixis price target lowered to $42 from $52 at H.C. Wainwright
02/18/22 Piper Sandler
Exelixis positioned for 'strong' 2022, says Piper Sandler
THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

03/07/22 Jefferies
Tenet Healthcare price target raised to $125 from $120 at Jefferies
03/03/22 Mizuho
Tenet Healthcare price target raised to $103 from $90 at Mizuho
03/01/22 Goldman Sachs
Tenet Healthcare reinstated with a Buy at Goldman Sachs
02/10/22 UBS
UBS upgrades Tenet on 'too attractive to ignore' cash flow
PFE Pfizer
$52.93 /

+0.69 (+1.32%)

02/15/22
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting
02/10/22 Mizuho
Pfizer price target lowered to $55 from $56 at Mizuho
02/09/22 Benchmark
Pfizer's Paxlovid forecast 'bodes well' for Codexis, says Benchmark
TCRX TScan Therapeutics
$3.55 /

-0.105 (-2.87%)

12/16/21 H.C. Wainwright
TScan Therapeutics initiated with a Buy at H.C. Wainwright
08/13/21 Cowen
Cowen sees upside for TScan Therapeutics, starts with Outperform
08/13/21 Cowen
TScan Therapeutics initiated with an Outperform at Cowen
08/10/21 Jefferies
TScan Therapeutics initiated with a Buy at Jefferies
VACC Vaccitech
$5.85 /

+0.59 (+11.22%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

03/16/22 JMP Securities
Vor Biopharma price target lowered to $30 from $40 at JMP Securities
01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

12/23/21 Canaccord
Sigilon Therapeutics price target lowered to $7 from $12 at Canaccord
12/01/21 Barclays
Sigilon Therapeutics price target lowered to $7 from $16 at Barclays
11/30/21 Jefferies
Sigilon downgraded to Hold at Jefferies after 'unexpected' fibrosis finding
11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
PIII P3 Health Partners
$6.85 /

+0.09 (+1.33%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
JANX Janux Therapeutics
$17.22 /

+0.19 (+1.12%)

07/06/21 Cowen
Cowen starts Janux with Outperform on potential of PSMA-TRACTr
07/06/21 BofA
Janux Therapeutics initiated with a Buy at BofA
07/06/21 Cowen
Janux Therapeutics initiated with an Outperform at Cowen
07/06/21 Evercore ISI
Evercore starts Janux Therapeutics at Outperform with $35 price target
KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

02/09/22 JPMorgan
Karyopharm upgraded to Neutral from Underweight at JPMorgan
11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
EOLS Evolus
$10.55 /

+0.61 (+6.14%)

01/26/22 Stifel
Evolus preannouncement shows continued execution success, says Stifel
01/20/22 Truist
Evolus upgraded to Buy from Hold at Truist
11/03/21 H.C. Wainwright
Evolus price target lowered to $15 from $22 at H.C. Wainwright
09/22/21 Stifel
Evolus positioned for aesthetics share increases through 2021, says Stifel
EPZM Epizyme
$1.31 /

+0.11 (+9.21%)

03/02/22 H.C. Wainwright
Epizyme price target lowered to $10 from $15 at H.C. Wainwright
09/09/21 Truist
MEI Pharma price target lowered to $8 from $12 at Truist
08/10/21 H.C. Wainwright
Epizyme price target lowered to $15 from $36 at H.C. Wainwright
08/09/21 Morgan Stanley
Epizyme downgraded to Underweight at Morgan Stanley on Tazverik challenges
BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

06/22/21 Stifel
Brookdale Senior Living resumed with a Buy at Stifel
06/11/21 Barclays
Brookdale Senior Living upgraded to Overweight from Equal Weight at Barclays
06/07/21 Jefferies
Approval of Biogen Alzheimer's drug could be catalyst for RadNet, says Jefferies
MTEM Molecular Templates
$2.50 /

+0.175 (+7.53%)

04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21 Jefferies
Jefferies views Molecular Templates selloff as overdone, boosts price target
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
LOGC LogicBio Therapeutics
/

+

02/03/22 William Blair
LogicBio downgraded to Market Perform on 'unfortunate setback' at William Blair
02/02/22 William Blair
LogicBio downgraded to Market Perform from Outperform at William Blair
11/17/21 Barclays
LogicBio Therapeutics price target lowered to $8 from $24 at Barclays
06/07/21
Fly Intel: Top five analyst initiations
VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

VACC Vaccitech
$5.85 /

+0.59 (+11.22%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

TCRX TScan Therapeutics
$3.55 /

-0.105 (-2.87%)

SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

PINC Premier
$35.67 /

+ (+0.00%)

PIII P3 Health Partners
$6.85 /

+0.09 (+1.33%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

PAHC Phibro Animal Health
$19.85 /

-0.17 (-0.85%)

MTEM Molecular Templates
$2.50 /

+0.175 (+7.53%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

EPZM Epizyme
$1.31 /

+0.11 (+9.21%)

EOLS Evolus
$10.55 /

+0.61 (+6.14%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

AZTA Azenta
$84.77 /

+7.52 (+9.73%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

  • 27
    Jan
  • 14
    Sep
  • 03
    Sep
  • 16
    Jul
  • 11
    Jun
  • 30
    Apr
  • 22
    Apr
PFE Pfizer
$52.93 /

+0.69 (+1.32%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

SGTX Sigilon Therapeutics
$1.42 /

+0.09 (+6.77%)

SGMO Sangamo
$5.54 /

+0.3 (+5.73%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

LNTH Lantheus
$54.99 /

+2.38 (+4.52%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

EXEL Exelixis
$20.65 /

+0.36 (+1.77%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

BKD Brookdale Senior Living
$6.79 /

-0.155 (-2.23%)

BEAM Beam Therapeutics
$59.83 /

+4.67 (+8.47%)

AVTR Avantor
$34.90 /

+0.42 (+1.22%)

ALNY Alnylam
$158.89 /

+5.92 (+3.87%)

VOR Vor Bio
$7.85 /

+0.17 (+2.21%)

THC Tenet Healthcare
$87.65 /

+0.22 (+0.25%)

PFE Pfizer
$52.93 /

+0.69 (+1.32%)

LLY Eli Lilly
$276.42 /

+0.87 (+0.32%)

KPTI Karyopharm
$6.67 /

+0.45 (+7.23%)

HUM Humana
$442.83 /

+2.9 (+0.66%)

CVS CVS Health
$107.14 /

+0.12 (+0.11%)

CNC Centene
$86.83 /

+1.27 (+1.48%)

AZTA Azenta
$84.77 /

+7.52 (+9.73%)

Conference/Events
Barclays to hold a conference » 04:55
03/16/22
03/16
04:55
03/16/22
04:55
AVTR

Avantor

$34.49 /

+0.42 (+1.23%)

, PAHC

Phibro Animal Health

$19.97 /

-0.23 (-1.14%)

, CVS

CVS Health

$107.02 /

+2.5 (+2.39%)

, ALNY

Alnylam

$153.00 /

+0.93 (+0.61%)

, LNTH

Lantheus

$52.55 /

+2.7 (+5.42%)

, BEAM

Beam Therapeutics

$55.15 /

+1.47 (+2.74%)

, HUM

Humana

$439.93 /

+7.93 (+1.84%)

, CNC

Centene

$85.56 /

+1.23 (+1.46%)

, LLY

Eli Lilly

$275.55 /

+6.57 (+2.44%)

, PINC

Premier

$35.67 /

+0.45 (+1.28%)

, AZTA

Azenta

$77.30 /

+0.97 (+1.27%)

, EXEL

Exelixis

$20.29 /

-0.29 (-1.41%)

, THC

Tenet Healthcare

$87.43 /

+1.23 (+1.43%)

, PFE

Pfizer

$52.25 /

+0.01 (+0.02%)

, TCRX

TScan Therapeutics

$3.66 /

-0.075 (-2.01%)

, VACC

Vaccitech

$5.26 /

-0.02 (-0.38%)

, VOR

Vor Bio

$7.71 /

+ (+0.00%)

, SGMO

Sangamo

$5.24 /

+ (+0.00%)

, SGTX

Sigilon Therapeutics

$1.33 /

+0.05 (+3.91%)

, PIII

P3 Health Partners

$6.67 /

+0.18 (+2.77%)

, JANX

Janux Therapeutics

$16.96 /

+0.13 (+0.77%)

, KPTI

Karyopharm

$6.22 /

+0.125 (+2.05%)

, EOLS

Evolus

$9.93 /

+0.39 (+4.09%)

, EPZM

Epizyme

$1.20 /

-0.01 (-0.83%)

, BKD

Brookdale Senior Living

$6.94 /

+0.035 (+0.51%)

, MTEM

Molecular Templates

$2.33 /

+0.07 (+3.10%)

, LOGC

LogicBio Therapeutics

/

+

Global Healthcare…

Global Healthcare Conference to be held in Miami, FL on March 15-17.

ShowHide Related Items >><<
VOR Vor Bio
$7.71 /

+ (+0.00%)

VACC Vaccitech
$5.26 /

-0.02 (-0.38%)

THC Tenet Healthcare
$87.43 /

+1.23 (+1.43%)

TCRX TScan Therapeutics
$3.66 /

-0.075 (-2.01%)

SGTX Sigilon Therapeutics
$1.33 /

+0.05 (+3.91%)

SGMO Sangamo
$5.24 /

+ (+0.00%)

PINC Premier
$35.67 /

+0.45 (+1.28%)

PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

PFE Pfizer
$52.25 /

+0.01 (+0.02%)

PAHC Phibro Animal Health
$19.97 /

-0.23 (-1.14%)

MTEM Molecular Templates
$2.33 /

+0.07 (+3.10%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$52.55 /

+2.7 (+5.42%)

LLY Eli Lilly
$275.55 /

+6.57 (+2.44%)

KPTI Karyopharm
$6.22 /

+0.125 (+2.05%)

JANX Janux Therapeutics
$16.96 /

+0.13 (+0.77%)

HUM Humana
$439.93 /

+7.93 (+1.84%)

EXEL Exelixis
$20.29 /

-0.29 (-1.41%)

EPZM Epizyme
$1.20 /

-0.01 (-0.83%)

EOLS Evolus
$9.93 /

+0.39 (+4.09%)

CVS CVS Health
$107.02 /

+2.5 (+2.39%)

CNC Centene
$85.56 /

+1.23 (+1.46%)

BKD Brookdale Senior Living
$6.94 /

+0.035 (+0.51%)

BEAM Beam Therapeutics
$55.15 /

+1.47 (+2.74%)

AZTA Azenta
$77.30 /

+0.97 (+1.27%)

AVTR Avantor
$34.49 /

+0.42 (+1.23%)

ALNY Alnylam
$153.00 /

+0.93 (+0.61%)

AVTR Avantor
$34.49 /

+0.42 (+1.23%)

02/07/22 Raymond James
Avantor price target lowered to $43 from $47 at Raymond James
02/07/22 Baird
Avantor price target lowered to $43 from $44 at Baird
02/07/22 Barclays
Avantor price target raised to $44 from $41 at Barclays
01/27/22 Barclays
Avantor price target lowered to $41 from $48 at Barclays
PAHC Phibro Animal Health
$19.97 /

-0.23 (-1.14%)

01/10/22 Barclays
Phibro Animal Health upgraded to Equal Weight from Underweight at Barclays
11/18/21 Morgan Stanley
Phibro Animal Health initiated with an Equal Weight at Morgan Stanley
08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
CVS CVS Health
$107.02 /

+2.5 (+2.39%)

03/09/22 UBS
Signify Health upgraded to Buy from Neutral at UBS
02/17/22 Deutsche Bank
CVS Health price target raised to $110 from $107 at Deutsche Bank
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
ALNY Alnylam
$153.00 /

+0.93 (+0.61%)

02/28/22 Citi
Alnylam initiated with a Buy at Citi
02/10/22 Piper Sandler
Piper Sandler 'confident' in approval of Alnylam's vutrisiran by PDUFA date
02/03/22 Guggenheim
Alnylam upgraded to Buy from Neutral at Guggenheim
01/20/22 H.C. Wainwright
Alnylam price target raised to $350 from $250 at H.C. Wainwright
LNTH Lantheus
$52.55 /

+2.7 (+5.42%)

BEAM Beam Therapeutics
$55.15 /

+1.47 (+2.74%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
HUM Humana
$439.93 /

+7.93 (+1.84%)

02/03/22 Deutsche Bank
Humana price target raised to $435 from $418 at Deutsche Bank
01/11/22 Bernstein
Humana price target lowered to $431 from $470 at Bernstein
01/07/22 Truist
Humana price target lowered to $445 from $520 at Truist
01/07/22 BMO Capital
Humana price target lowered to $415 from $490 at BMO Capital
CNC Centene
$85.56 /

+1.23 (+1.46%)

02/09/22 Deutsche Bank
Centene price target raised to $88 from $84 at Deutsche Bank
02/09/22 BMO Capital
Centene price target raised to $105 from $100 at BMO Capital
02/09/22 Mizuho
Centene price target raised to $84 from $78 at Mizuho
02/04/22 Wells Fargo
Anthem, Centene have 'significant' exposure to CA Medicaid, says Wells Fargo
LLY Eli Lilly
$275.55 /

+6.57 (+2.44%)

03/10/22 Daiwa
Eli Lilly initiated with an Outperform at Daiwa
03/02/22 Goldman Sachs
Quanterix upgraded to Neutral from Sell at Goldman Sachs
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
02/11/22 Benchmark
AbCellera royalties could be 'substantial' from Lilly antibody, says Benchmark
PINC Premier
$35.67 /

+0.45 (+1.28%)

11/18/21 Barclays
Premier price target raised to $36 from $34 at Barclays
11/03/21 Piper Sandler
Premier price target raised to $39 from $31 at Piper Sandler
05/28/21
Fly Intel: Top five analyst downgrades
05/28/21 Barclays
Barclays double downgrades Premier with multiple expansion less likely
AZTA Azenta
$77.30 /

+0.97 (+1.27%)

02/09/22 Needham
Azenta price target lowered to $115 from $155 at Needham
11/17/21 Stifel
Brooks Automation price target raised to $149 from $134 at Stifel
11/17/21 Stephens
Brooks Automation price target raised to $137 from $130 at Stephens
EXEL Exelixis
$20.29 /

-0.29 (-1.41%)

03/14/22 Piper Sandler
Exelixis price target lowered to $30 from $34 at Piper Sandler
02/25/22 Jefferies
Court denied MSN motion to add patents to fight with Exelixis, says Jefferies
02/18/22 H.C. Wainwright
Exelixis price target lowered to $42 from $52 at H.C. Wainwright
02/18/22 Piper Sandler
Exelixis positioned for 'strong' 2022, says Piper Sandler
THC Tenet Healthcare
$87.43 /

+1.23 (+1.43%)

03/07/22 Jefferies
Tenet Healthcare price target raised to $125 from $120 at Jefferies
03/03/22 Mizuho
Tenet Healthcare price target raised to $103 from $90 at Mizuho
03/01/22 Goldman Sachs
Tenet Healthcare reinstated with a Buy at Goldman Sachs
02/10/22 UBS
UBS upgrades Tenet on 'too attractive to ignore' cash flow
PFE Pfizer
$52.25 /

+0.01 (+0.02%)

02/15/22
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting
02/10/22 Mizuho
Pfizer price target lowered to $55 from $56 at Mizuho
02/09/22 Benchmark
Pfizer's Paxlovid forecast 'bodes well' for Codexis, says Benchmark
TCRX TScan Therapeutics
$3.66 /

-0.075 (-2.01%)

12/16/21 H.C. Wainwright
TScan Therapeutics initiated with a Buy at H.C. Wainwright
08/13/21 Cowen
Cowen sees upside for TScan Therapeutics, starts with Outperform
08/13/21 Cowen
TScan Therapeutics initiated with an Outperform at Cowen
08/10/21 Jefferies
TScan Therapeutics initiated with a Buy at Jefferies
VACC Vaccitech
$5.26 /

-0.02 (-0.38%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$7.71 /

+ (+0.00%)

01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
12/02/21 Baird
Vor Biopharma initiated with an Outperform at Baird
SGMO Sangamo
$5.24 /

+ (+0.00%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
SGTX Sigilon Therapeutics
$1.33 /

+0.05 (+3.91%)

12/23/21 Canaccord
Sigilon Therapeutics price target lowered to $7 from $12 at Canaccord
12/01/21 Barclays
Sigilon Therapeutics price target lowered to $7 from $16 at Barclays
11/30/21 Jefferies
Sigilon downgraded to Hold at Jefferies after 'unexpected' fibrosis finding
11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
JANX Janux Therapeutics
$16.96 /

+0.13 (+0.77%)

07/06/21 Cowen
Cowen starts Janux with Outperform on potential of PSMA-TRACTr
07/06/21 BofA
Janux Therapeutics initiated with a Buy at BofA
07/06/21 Cowen
Janux Therapeutics initiated with an Outperform at Cowen
07/06/21 Evercore ISI
Evercore starts Janux Therapeutics at Outperform with $35 price target
KPTI Karyopharm
$6.22 /

+0.125 (+2.05%)

02/09/22 JPMorgan
Karyopharm upgraded to Neutral from Underweight at JPMorgan
11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
EOLS Evolus
$9.93 /

+0.39 (+4.09%)

01/26/22 Stifel
Evolus preannouncement shows continued execution success, says Stifel
01/20/22 Truist
Evolus upgraded to Buy from Hold at Truist
11/03/21 H.C. Wainwright
Evolus price target lowered to $15 from $22 at H.C. Wainwright
09/22/21 Stifel
Evolus positioned for aesthetics share increases through 2021, says Stifel
EPZM Epizyme
$1.20 /

-0.01 (-0.83%)

03/02/22 H.C. Wainwright
Epizyme price target lowered to $10 from $15 at H.C. Wainwright
09/09/21 Truist
MEI Pharma price target lowered to $8 from $12 at Truist
08/10/21 H.C. Wainwright
Epizyme price target lowered to $15 from $36 at H.C. Wainwright
08/09/21 Morgan Stanley
Epizyme downgraded to Underweight at Morgan Stanley on Tazverik challenges
BKD Brookdale Senior Living
$6.94 /

+0.035 (+0.51%)

06/22/21 Stifel
Brookdale Senior Living resumed with a Buy at Stifel
06/11/21 Barclays
Brookdale Senior Living upgraded to Overweight from Equal Weight at Barclays
06/07/21 Jefferies
Approval of Biogen Alzheimer's drug could be catalyst for RadNet, says Jefferies
MTEM Molecular Templates
$2.33 /

+0.07 (+3.10%)

04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21 Jefferies
Jefferies views Molecular Templates selloff as overdone, boosts price target
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
LOGC LogicBio Therapeutics
/

+

02/03/22 William Blair
LogicBio downgraded to Market Perform on 'unfortunate setback' at William Blair
02/02/22 William Blair
LogicBio downgraded to Market Perform from Outperform at William Blair
11/17/21 Barclays
LogicBio Therapeutics price target lowered to $8 from $24 at Barclays
06/07/21
Fly Intel: Top five analyst initiations
VOR Vor Bio
$7.71 /

+ (+0.00%)

VACC Vaccitech
$5.26 /

-0.02 (-0.38%)

THC Tenet Healthcare
$87.43 /

+1.23 (+1.43%)

TCRX TScan Therapeutics
$3.66 /

-0.075 (-2.01%)

SGTX Sigilon Therapeutics
$1.33 /

+0.05 (+3.91%)

SGMO Sangamo
$5.24 /

+ (+0.00%)

PINC Premier
$35.67 /

+0.45 (+1.28%)

PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

PFE Pfizer
$52.25 /

+0.01 (+0.02%)

PAHC Phibro Animal Health
$19.97 /

-0.23 (-1.14%)

MTEM Molecular Templates
$2.33 /

+0.07 (+3.10%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$52.55 /

+2.7 (+5.42%)

LLY Eli Lilly
$275.55 /

+6.57 (+2.44%)

KPTI Karyopharm
$6.22 /

+0.125 (+2.05%)

HUM Humana
$439.93 /

+7.93 (+1.84%)

EXEL Exelixis
$20.29 /

-0.29 (-1.41%)

EPZM Epizyme
$1.20 /

-0.01 (-0.83%)

EOLS Evolus
$9.93 /

+0.39 (+4.09%)

CVS CVS Health
$107.02 /

+2.5 (+2.39%)

CNC Centene
$85.56 /

+1.23 (+1.46%)

BKD Brookdale Senior Living
$6.94 /

+0.035 (+0.51%)

BEAM Beam Therapeutics
$55.15 /

+1.47 (+2.74%)

AZTA Azenta
$77.30 /

+0.97 (+1.27%)

AVTR Avantor
$34.49 /

+0.42 (+1.23%)

ALNY Alnylam
$153.00 /

+0.93 (+0.61%)

  • 27
    Jan
  • 14
    Sep
  • 03
    Sep
  • 16
    Jul
  • 11
    Jun
  • 30
    Apr
  • 22
    Apr
PFE Pfizer
$52.25 /

+0.01 (+0.02%)

LLY Eli Lilly
$275.55 /

+6.57 (+2.44%)

HUM Humana
$439.93 /

+7.93 (+1.84%)

CVS CVS Health
$107.02 /

+2.5 (+2.39%)

CNC Centene
$85.56 /

+1.23 (+1.46%)

THC Tenet Healthcare
$87.43 /

+1.23 (+1.43%)

SGTX Sigilon Therapeutics
$1.33 /

+0.05 (+3.91%)

SGMO Sangamo
$5.24 /

+ (+0.00%)

PFE Pfizer
$52.25 /

+0.01 (+0.02%)

LNTH Lantheus
$52.55 /

+2.7 (+5.42%)

LLY Eli Lilly
$275.55 /

+6.57 (+2.44%)

KPTI Karyopharm
$6.22 /

+0.125 (+2.05%)

HUM Humana
$439.93 /

+7.93 (+1.84%)

EXEL Exelixis
$20.29 /

-0.29 (-1.41%)

CVS CVS Health
$107.02 /

+2.5 (+2.39%)

CNC Centene
$85.56 /

+1.23 (+1.46%)

BKD Brookdale Senior Living
$6.94 /

+0.035 (+0.51%)

BEAM Beam Therapeutics
$55.15 /

+1.47 (+2.74%)

AVTR Avantor
$34.49 /

+0.42 (+1.23%)

ALNY Alnylam
$153.00 /

+0.93 (+0.61%)

VOR Vor Bio
$7.71 /

+ (+0.00%)

THC Tenet Healthcare
$87.43 /

+1.23 (+1.43%)

PFE Pfizer
$52.25 /

+0.01 (+0.02%)

LLY Eli Lilly
$275.55 /

+6.57 (+2.44%)

KPTI Karyopharm
$6.22 /

+0.125 (+2.05%)

HUM Humana
$439.93 /

+7.93 (+1.84%)

CVS CVS Health
$107.02 /

+2.5 (+2.39%)

CNC Centene
$85.56 /

+1.23 (+1.46%)

AZTA Azenta
$77.30 /

+0.97 (+1.27%)

Conference/Events
Barclays to hold a conference » 04:55
03/15/22
03/15
04:55
03/15/22
04:55
AVTR

Avantor

$34.06 /

+0.185 (+0.55%)

, PAHC

Phibro Animal Health

$20.20 /

+0.14 (+0.70%)

, CVS

CVS Health

$104.52 /

+1.09 (+1.05%)

, ALNY

Alnylam

$151.71 /

-3.185 (-2.06%)

, LNTH

Lantheus

$49.88 /

-2.07 (-3.98%)

, BEAM

Beam Therapeutics

$53.69 /

-7.01 (-11.55%)

, HUM

Humana

$431.91 /

+5.8 (+1.36%)

, CNC

Centene

$84.33 /

+0.87 (+1.04%)

, LLY

Eli Lilly

$268.98 /

+2.855 (+1.07%)

, PINC

Premier

$35.25 /

-0.09 (-0.25%)

, AZTA

Azenta

$76.26 /

-1.81 (-2.32%)

, EXEL

Exelixis

$20.59 /

-0.415 (-1.98%)

, THC

Tenet Healthcare

$86.21 /

-2.89 (-3.24%)

, PFE

Pfizer

$52.24 /

+1.96 (+3.90%)

, TCRX

TScan Therapeutics

$3.74 /

-0.26 (-6.50%)

, VACC

Vaccitech

$5.28 /

-0.01 (-0.19%)

, VOR

Vor Bio

$7.71 /

-0.8 (-9.40%)

, SGMO

Sangamo

$5.24 /

-0.35 (-6.26%)

, SGTX

Sigilon Therapeutics

$1.28 /

-0.03 (-2.29%)

, PIII

P3 Health Partners

$6.47 /

-0.385 (-5.62%)

, JANX

Janux Therapeutics

$16.80 /

-0.71 (-4.05%)

, KPTI

Karyopharm

$6.10 /

-0.225 (-3.56%)

, EOLS

Evolus

$9.50 /

-0.57 (-5.66%)

, EPZM

Epizyme

$1.21 /

-0.16 (-11.72%)

, BKD

Brookdale Senior Living

$6.90 /

-0.285 (-3.97%)

, MTEM

Molecular Templates

$2.25 /

-0.21 (-8.54%)

, LOGC

LogicBio Therapeutics

/

+

Global Healthcare…

Global Healthcare Conference to be held in Miami, FL on March 15-17.

ShowHide Related Items >><<
VOR Vor Bio
$7.71 /

-0.8 (-9.40%)

VACC Vaccitech
$5.28 /

-0.01 (-0.19%)

THC Tenet Healthcare
$86.21 /

-2.89 (-3.24%)

TCRX TScan Therapeutics
$3.74 /

-0.26 (-6.50%)

SGTX Sigilon Therapeutics
$1.28 /

-0.03 (-2.29%)

SGMO Sangamo
$5.24 /

-0.35 (-6.26%)

PINC Premier
$35.25 /

-0.09 (-0.25%)

PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

PFE Pfizer
$52.24 /

+1.96 (+3.90%)

PAHC Phibro Animal Health
$20.20 /

+0.14 (+0.70%)

MTEM Molecular Templates
$2.25 /

-0.21 (-8.54%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$49.88 /

-2.07 (-3.98%)

LLY Eli Lilly
$268.98 /

+2.855 (+1.07%)

KPTI Karyopharm
$6.10 /

-0.225 (-3.56%)

JANX Janux Therapeutics
$16.80 /

-0.71 (-4.05%)

HUM Humana
$431.91 /

+5.8 (+1.36%)

EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

EPZM Epizyme
$1.21 /

-0.16 (-11.72%)

EOLS Evolus
$9.50 /

-0.57 (-5.66%)

CVS CVS Health
$104.52 /

+1.09 (+1.05%)

CNC Centene
$84.33 /

+0.87 (+1.04%)

BKD Brookdale Senior Living
$6.90 /

-0.285 (-3.97%)

BEAM Beam Therapeutics
$53.69 /

-7.01 (-11.55%)

AZTA Azenta
$76.26 /

-1.81 (-2.32%)

AVTR Avantor
$34.06 /

+0.185 (+0.55%)

ALNY Alnylam
$151.71 /

-3.185 (-2.06%)

AVTR Avantor
$34.06 /

+0.185 (+0.55%)

02/07/22 Raymond James
Avantor price target lowered to $43 from $47 at Raymond James
02/07/22 Baird
Avantor price target lowered to $43 from $44 at Baird
02/07/22 Barclays
Avantor price target raised to $44 from $41 at Barclays
01/27/22 Barclays
Avantor price target lowered to $41 from $48 at Barclays
PAHC Phibro Animal Health
$20.20 /

+0.14 (+0.70%)

01/10/22 Barclays
Phibro Animal Health upgraded to Equal Weight from Underweight at Barclays
11/18/21 Morgan Stanley
Phibro Animal Health initiated with an Equal Weight at Morgan Stanley
08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
CVS CVS Health
$104.52 /

+1.09 (+1.05%)

03/09/22 UBS
Signify Health upgraded to Buy from Neutral at UBS
02/17/22 Deutsche Bank
CVS Health price target raised to $110 from $107 at Deutsche Bank
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
02/11/22 Raymond James
CVS Health downgraded to Outperform from Strong Buy at Raymond James
ALNY Alnylam
$151.71 /

-3.185 (-2.06%)

02/28/22 Citi
Alnylam initiated with a Buy at Citi
02/10/22 Piper Sandler
Piper Sandler 'confident' in approval of Alnylam's vutrisiran by PDUFA date
02/03/22 Guggenheim
Alnylam upgraded to Buy from Neutral at Guggenheim
01/20/22 H.C. Wainwright
Alnylam price target raised to $350 from $250 at H.C. Wainwright
LNTH Lantheus
$49.88 /

-2.07 (-3.98%)

BEAM Beam Therapeutics
$53.69 /

-7.01 (-11.55%)

01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 Guggenheim
Guggenheim starts Beam Therapeutics with a Buy rating, $130 price target
01/05/22 Guggenheim
Beam Therapeutics initiated with a Buy at Guggenheim
10/19/21 SVB Leerink
Beam Therapeutics initiated with an Outperform at SVB Leerink
HUM Humana
$431.91 /

+5.8 (+1.36%)

02/03/22 Deutsche Bank
Humana price target raised to $435 from $418 at Deutsche Bank
01/11/22 Bernstein
Humana price target lowered to $431 from $470 at Bernstein
01/07/22 Truist
Humana price target lowered to $445 from $520 at Truist
01/07/22 BMO Capital
Humana price target lowered to $415 from $490 at BMO Capital
CNC Centene
$84.33 /

+0.87 (+1.04%)

02/09/22 Deutsche Bank
Centene price target raised to $88 from $84 at Deutsche Bank
02/09/22 BMO Capital
Centene price target raised to $105 from $100 at BMO Capital
02/09/22 Mizuho
Centene price target raised to $84 from $78 at Mizuho
02/04/22 Wells Fargo
Anthem, Centene have 'significant' exposure to CA Medicaid, says Wells Fargo
LLY Eli Lilly
$268.98 /

+2.855 (+1.07%)

03/10/22 Daiwa
Eli Lilly initiated with an Outperform at Daiwa
03/02/22 Goldman Sachs
Quanterix upgraded to Neutral from Sell at Goldman Sachs
02/14/22 JMP Securities
ProQR Therapeutics price target lowered to $8 from $29 at JMP Securities
02/11/22 Benchmark
AbCellera royalties could be 'substantial' from Lilly antibody, says Benchmark
PINC Premier
$35.25 /

-0.09 (-0.25%)

11/18/21 Barclays
Premier price target raised to $36 from $34 at Barclays
11/03/21 Piper Sandler
Premier price target raised to $39 from $31 at Piper Sandler
05/28/21
Fly Intel: Top five analyst downgrades
05/28/21 Barclays
Barclays double downgrades Premier with multiple expansion less likely
AZTA Azenta
$76.26 /

-1.81 (-2.32%)

02/09/22 Needham
Azenta price target lowered to $115 from $155 at Needham
11/17/21 Stifel
Brooks Automation price target raised to $149 from $134 at Stifel
11/17/21 Stephens
Brooks Automation price target raised to $137 from $130 at Stephens
EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

03/14/22 Piper Sandler
Exelixis price target lowered to $30 from $34 at Piper Sandler
02/25/22 Jefferies
Court denied MSN motion to add patents to fight with Exelixis, says Jefferies
02/18/22 H.C. Wainwright
Exelixis price target lowered to $42 from $52 at H.C. Wainwright
02/18/22 Piper Sandler
Exelixis positioned for 'strong' 2022, says Piper Sandler
THC Tenet Healthcare
$86.21 /

-2.89 (-3.24%)

03/07/22 Jefferies
Tenet Healthcare price target raised to $125 from $120 at Jefferies
03/03/22 Mizuho
Tenet Healthcare price target raised to $103 from $90 at Mizuho
03/01/22 Goldman Sachs
Tenet Healthcare reinstated with a Buy at Goldman Sachs
02/10/22 UBS
UBS upgrades Tenet on 'too attractive to ignore' cash flow
PFE Pfizer
$52.24 /

+1.96 (+3.90%)

02/15/22
FDA Vaccines and Related Biological Products Advisory Committee to hold meeting
02/10/22 Mizuho
Pfizer price target lowered to $55 from $56 at Mizuho
02/09/22 Benchmark
Pfizer's Paxlovid forecast 'bodes well' for Codexis, says Benchmark
TCRX TScan Therapeutics
$3.74 /

-0.26 (-6.50%)

12/16/21 H.C. Wainwright
TScan Therapeutics initiated with a Buy at H.C. Wainwright
08/13/21 Cowen
Cowen sees upside for TScan Therapeutics, starts with Outperform
08/13/21 Cowen
TScan Therapeutics initiated with an Outperform at Cowen
08/10/21 Jefferies
TScan Therapeutics initiated with a Buy at Jefferies
VACC Vaccitech
$5.28 /

-0.01 (-0.19%)

05/25/21 William Blair
Vaccitech initiated with an Outperform at William Blair
05/25/21 Morgan Stanley
Vaccitech initiated with an Overweight at Morgan Stanley
05/25/21 Jefferies
Vaccitech initiated with a Buy at Jefferies
05/24/21 H.C. Wainwright
Vaccitech initiated with a Buy at H.C. Wainwright
VOR Vor Bio
$7.71 /

-0.8 (-9.40%)

01/24/22 B. Riley
Vor Biopharma price target lowered to $46 from $60 at B. Riley
12/17/21 H.C. Wainwright
Vor Biopharma initiated with a Buy at H.C. Wainwright
12/03/21 Baird
Baird start Vor Biopharma with an Outperform ahead of AML data
12/02/21 Baird
Vor Biopharma initiated with an Outperform at Baird
SGMO Sangamo
$5.24 /

-0.35 (-6.26%)

01/06/22 Stifel
Sangamo price target lowered to $6 from $9 at Stifel
05/03/21 RBC Capital
Sangamo initiated with an Outperform at RBC Capital
SGTX Sigilon Therapeutics
$1.28 /

-0.03 (-2.29%)

12/23/21 Canaccord
Sigilon Therapeutics price target lowered to $7 from $12 at Canaccord
12/01/21 Barclays
Sigilon Therapeutics price target lowered to $7 from $16 at Barclays
11/30/21 Jefferies
Sigilon downgraded to Hold at Jefferies after 'unexpected' fibrosis finding
11/30/21 Canaccord
Sigilon Therapeutics price target lowered to $12 from $23 at Canaccord
PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
JANX Janux Therapeutics
$16.80 /

-0.71 (-4.05%)

07/06/21 Cowen
Cowen starts Janux with Outperform on potential of PSMA-TRACTr
07/06/21 BofA
Janux Therapeutics initiated with a Buy at BofA
07/06/21 Cowen
Janux Therapeutics initiated with an Outperform at Cowen
07/06/21 Evercore ISI
Evercore starts Janux Therapeutics at Outperform with $35 price target
KPTI Karyopharm
$6.10 /

-0.225 (-3.56%)

02/09/22 JPMorgan
Karyopharm upgraded to Neutral from Underweight at JPMorgan
11/19/21 Morgan Stanley
Karyopharm assumed at Equal Weight from Overweight at Morgan Stanley
08/06/21 JPMorgan
JPMorgan double downgrades Karyopharm on Xpovio weakness
08/06/21 Baird
Karyopharm price target lowered to $17 from $30 at Baird
EOLS Evolus
$9.50 /

-0.57 (-5.66%)

01/26/22 Stifel
Evolus preannouncement shows continued execution success, says Stifel
01/20/22 Truist
Evolus upgraded to Buy from Hold at Truist
11/03/21 H.C. Wainwright
Evolus price target lowered to $15 from $22 at H.C. Wainwright
09/22/21 Stifel
Evolus positioned for aesthetics share increases through 2021, says Stifel
EPZM Epizyme
$1.21 /

-0.16 (-11.72%)

03/02/22 H.C. Wainwright
Epizyme price target lowered to $10 from $15 at H.C. Wainwright
09/09/21 Truist
MEI Pharma price target lowered to $8 from $12 at Truist
08/10/21 H.C. Wainwright
Epizyme price target lowered to $15 from $36 at H.C. Wainwright
08/09/21 Morgan Stanley
Epizyme downgraded to Underweight at Morgan Stanley on Tazverik challenges
BKD Brookdale Senior Living
$6.90 /

-0.285 (-3.97%)

06/22/21 Stifel
Brookdale Senior Living resumed with a Buy at Stifel
06/11/21 Barclays
Brookdale Senior Living upgraded to Overweight from Equal Weight at Barclays
06/07/21 Jefferies
Approval of Biogen Alzheimer's drug could be catalyst for RadNet, says Jefferies
MTEM Molecular Templates
$2.25 /

-0.21 (-8.54%)

04/21/21 BofA
Molecular Templates initiated with a Buy at BofA
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21 Jefferies
Jefferies views Molecular Templates selloff as overdone, boosts price target
04/05/21 Barclays
Molecular Templates MT-3724 discontinuation shouldn't be surprise, says Barclays
LOGC LogicBio Therapeutics
/

+

02/03/22 William Blair
LogicBio downgraded to Market Perform on 'unfortunate setback' at William Blair
02/02/22 William Blair
LogicBio downgraded to Market Perform from Outperform at William Blair
11/17/21 Barclays
LogicBio Therapeutics price target lowered to $8 from $24 at Barclays
06/07/21
Fly Intel: Top five analyst initiations
VOR Vor Bio
$7.71 /

-0.8 (-9.40%)

VACC Vaccitech
$5.28 /

-0.01 (-0.19%)

THC Tenet Healthcare
$86.21 /

-2.89 (-3.24%)

TCRX TScan Therapeutics
$3.74 /

-0.26 (-6.50%)

SGTX Sigilon Therapeutics
$1.28 /

-0.03 (-2.29%)

SGMO Sangamo
$5.24 /

-0.35 (-6.26%)

PINC Premier
$35.25 /

-0.09 (-0.25%)

PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

PFE Pfizer
$52.24 /

+1.96 (+3.90%)

PAHC Phibro Animal Health
$20.20 /

+0.14 (+0.70%)

MTEM Molecular Templates
$2.25 /

-0.21 (-8.54%)

LOGC LogicBio Therapeutics
/

+

LNTH Lantheus
$49.88 /

-2.07 (-3.98%)

LLY Eli Lilly
$268.98 /

+2.855 (+1.07%)

KPTI Karyopharm
$6.10 /

-0.225 (-3.56%)

HUM Humana
$431.91 /

+5.8 (+1.36%)

EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

EPZM Epizyme
$1.21 /

-0.16 (-11.72%)

EOLS Evolus
$9.50 /

-0.57 (-5.66%)

CVS CVS Health
$104.52 /

+1.09 (+1.05%)

CNC Centene
$84.33 /

+0.87 (+1.04%)

BKD Brookdale Senior Living
$6.90 /

-0.285 (-3.97%)

BEAM Beam Therapeutics
$53.69 /

-7.01 (-11.55%)

AZTA Azenta
$76.26 /

-1.81 (-2.32%)

AVTR Avantor
$34.06 /

+0.185 (+0.55%)

ALNY Alnylam
$151.71 /

-3.185 (-2.06%)

  • 27
    Jan
  • 14
    Sep
  • 03
    Sep
  • 16
    Jul
  • 11
    Jun
  • 30
    Apr
  • 22
    Apr
PFE Pfizer
$52.24 /

+1.96 (+3.90%)

LLY Eli Lilly
$268.98 /

+2.855 (+1.07%)

HUM Humana
$431.91 /

+5.8 (+1.36%)

CVS CVS Health
$104.52 /

+1.09 (+1.05%)

CNC Centene
$84.33 /

+0.87 (+1.04%)

THC Tenet Healthcare
$86.21 /

-2.89 (-3.24%)

SGTX Sigilon Therapeutics
$1.28 /

-0.03 (-2.29%)

SGMO Sangamo
$5.24 /

-0.35 (-6.26%)

PFE Pfizer
$52.24 /

+1.96 (+3.90%)

LNTH Lantheus
$49.88 /

-2.07 (-3.98%)

LLY Eli Lilly
$268.98 /

+2.855 (+1.07%)

KPTI Karyopharm
$6.10 /

-0.225 (-3.56%)

HUM Humana
$431.91 /

+5.8 (+1.36%)

EXEL Exelixis
$20.59 /

-0.415 (-1.98%)

CVS CVS Health
$104.52 /

+1.09 (+1.05%)

CNC Centene
$84.33 /

+0.87 (+1.04%)

BKD Brookdale Senior Living
$6.90 /

-0.285 (-3.97%)

BEAM Beam Therapeutics
$53.69 /

-7.01 (-11.55%)

AVTR Avantor
$34.06 /

+0.185 (+0.55%)

ALNY Alnylam
$151.71 /

-3.185 (-2.06%)

VOR Vor Bio
$7.71 /

-0.8 (-9.40%)

THC Tenet Healthcare
$86.21 /

-2.89 (-3.24%)

PFE Pfizer
$52.24 /

+1.96 (+3.90%)

LLY Eli Lilly
$268.98 /

+2.855 (+1.07%)

KPTI Karyopharm
$6.10 /

-0.225 (-3.56%)

HUM Humana
$431.91 /

+5.8 (+1.36%)

CVS CVS Health
$104.52 /

+1.09 (+1.05%)

CNC Centene
$84.33 /

+0.87 (+1.04%)

AZTA Azenta
$76.26 /

-1.81 (-2.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.